89BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.26 USD | +0.12% |
|
-9.03% | -26.05% |
| 17/04 | 89bio, Inc. Appoints Martin Babler to Its Board of Directors | CI |
| 03/04 | 89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing | MT |
| Sales 2024 * | 938K 78.17M | Sales 2025 * | 2.19M 182M | Capitalization | 787M 65.58B |
|---|---|---|---|---|---|
| Net income 2024 * | -194M -16.18B | Net income 2025 * | -254M -21.18B | EV / Sales 2024 * | 411 x |
| Net cash position 2024 * | 401M 33.45B | Net cash position 2025 * | 190M 15.85B | EV / Sales 2025 * | 273 x |
| P/E ratio 2024 * |
-3.73
x | P/E ratio 2025 * |
-3.04
x | Employees | 70 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.12% | ||
| 1 week | -9.03% | ||
| Current month | -29.04% | ||
| 1 month | -26.25% | ||
| 3 months | -18.78% | ||
| 6 months | +20.23% | ||
| Current year | -26.05% |
1 week
8.04
9.78
1 month
8.0411.69
Current year
7.4716.63
1 year
6.5822.93
3 years
2.0027.99
5 years
2.0047.25
10 years
2.0047.25
| Managers | Title | Age | Since |
|---|---|---|---|
Rohan Palekar
CEO | Chief Executive Officer | 58 | 01/18/01 |
Ryan Martins
DFI | Director of Finance/CFO | 47 | 01/19/01 |
Paul Shin
COO | Chief Operating Officer | - | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 01/20/01 |
Rohan Palekar
CEO | Chief Executive Officer | 58 | 01/18/01 |
Kathy LaPorte
BRD | Director/Board Member | 62 | 01/21/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.01% | 4 M€ | -5.15% | - | |
| 0.05% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 8.26 | +0.12% | 653,066 |
| 25/24/25 | 8.25 | -3.85% | 1,012,055 |
| 24/24/24 | 8.58 | -3.81% | 871,176 |
| 23/24/23 | 8.92 | -4.19% | 745,431 |
| 22/24/22 | 9.31 | +2.53% | 580,198 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Companyâs lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.26
USD
Average target price
31.89
USD
Spread / Average Target
+286.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.05% | 787M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ETNB Stock
